#United States #Orlando #Zepbound #Eli Lilly #Taltz

Eli Lilly's Upcoming Presentation at ACR Convergence 2026

Eli Lilly and Company (NYSE: LLY) is preparing to showcase cutting-edge clinical data during the American College of Rheumatology (ACR) Convergence 2026, taking place from November 6 to 11 in Orlando. The company will present innovative research focused on treating knee osteoarthritis pain associated with obesity and psoriatic arthritis, targeting the critical relationship between rheumatologic conditions and obesity.

Key Findings from Clinical Trials

Among the highlights are findings from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials involving retatrutide. This investigational treatment is proven to significantly reduce both knee pain and body weight in adults suffering from knee osteoarthritis and obesity, with some participants reporting no knee pain by the study's end. Notably, retatrutide acts as a once-weekly triple hormone receptor agonist, targeting multiple pathways to improve patient outcomes.

In conjunction with retatrutide, Lilly will also present positive data regarding the combination of Taltz (ixekizumab) and Zepbound (tirzepatide). The comprehensive findings from the Phase 3b TOGETHER-PsA trial demonstrate the efficacy of combining these two treatments for adults with psoriatic arthritis and obesity. Notably, the results suggest enhancements across various metrics, including disease activity and patient-reported outcomes over one year.

The Bigger Picture: Addressing Obesity and Rheumatologic Conditions

Adrienne Brown, Executive Vice President and President of Lilly Immunology, noted the significant impact obesity has on managing rheumatologic diseases like knee osteoarthritis and psoriatic arthritis. Roughly 80% of individuals with knee osteoarthritis also have obesity or overweight, which exacerbates pain and functionality issues. It’s estimated that around 65% of people with psoriatic arthritis are similarly affected, underscoring the vital need for integrated treatment approaches.

Lilly's research underscores a commitment to advancing immunometabolic health by exploring innovative therapies that confront the intertwined nature of these conditions. The intention is to better the quality of life for those grappling with these debilitating issues.

Presentation Highlights

During ACR Convergence 2026, Lilly’s presentations will include:

• - Retatrutide Plenary Session: Scheduled for November 8, 2026, detailing how retatrutide significantly alleviated knee pain and improved physical function in patients with osteoarthritis and obesity.
• - Taltz and Zepbound Oral Presentation: On November 11, this session will shed light on the joint efficacy of these two investigational treatments in addressing psoriatic arthritis coupled with obesity, spotlighting improved patient outcomes.

These presentations align with guidelines advocating for weight loss as part of treatment strategies for these conditions, making a compelling case for integrated solutions that acknowledge the dual burden on patients.

The Future of Treatment Options

The data to be presented at ACR Convergence 2026 could change the landscape for managing not only obesity but also related rheumatologic conditions. Eli Lilly’s ongoing commitment to rigorous research drives the exploration of promising new interventions that could redefine the quality of life for millions.

For more updates on these presentations and to delve deeper into Lilly’s innovative therapies, keep an eye on their official website, where the latest findings and resources will be available following the conference.